News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NeoGenomics, Inc. (NGNM.OB) Reports 42% Test Volume Growth, 26% Revenue Growth and 22% Increase in Adjusted EBITDA for the Third Quarter 2012


10/31/2012 9:20:24 AM

FT. MYERS, Fla., Oct. 31, 2012 /PRNewswire/ -- NeoGenomics, Inc. (NASD OTC QB: NGNM), a leading provider of cancer genetic testing services today reported its results for the third quarter 2012.

Third Quarter 2012 Highlights:
42% Test Volume Growth
26% Revenue Growth
22% Increase in Adjusted EBITDA
Net Loss of ($0.02) per Share Due to Impacts from TC Grandfather Expiration
New California Laboratory Location Opened


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES